Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Macugen NDA accepted for review

Aug. 23, 2004

Pfizer scientists describe new antiangiogenic agents for ocular disorders

Aug. 19, 2004

Acuity files IND for phase I trials of Cand5

Aug. 16, 2004

Approvable letter for ZyLET

Aug. 11, 2004

Hybridon licenses VEGF rights to Alnylam for ocular indications

Aug. 10, 2004

Ista submits sNDA for Vitrase as spreading agent

Aug. 10, 2004

Approvable letter for Lumigan-timolol combination

Aug. 5, 2004

Alcon patent covers new 5-HT2 agonists for glaucoma therapy

Aug. 5, 2004

ISTA launches Istalol for glaucoma

Aug. 2, 2004

FDA accepts for review Xibrom NDA

July 28, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 13, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.
LINC01116 has prognostic value in lung cancer, study shows
BioWorld MedTech
Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...